CLOV Company Profile and Key Details

CLOV has shown mixed momentum, losing -1.89% over the past week and -4.43% over the past quarter, though year-to-date performance is up 10.21%. Short-term trend indicators are bullishly aligned (SMA20 2.63%, SMA50 -9.14%, SMA200 -22.0%). The stock’s 14-day RSI is 47.53 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.43% below its high and over 10.82% above its low. Average 10-day trading volume of 5.54 million shares is slightly above the 3-month average of 4.97 million, indicating heightened recent market interest.

Clover Health Investments, Corp. has 435.44 million shares outstanding. The public float is 412.92 million shares, elevated short interest at 5.64% of float. This equals 23.68 million shares. The short ratio is 5.5 days. Institutional investors hold 31.4% of the float. Insiders own 4.3%. Toy Andrew holds 9.46 million shares, Reynoso Jamie L. has 2.81 million shares and Priest Brady Patrick has 2.04 million shares. Over the past six months, insider transactions show net selling. They sold 1.36 million shares across 25 transactions.

Clover Health Investments, Corp. generated EPS of -$0.12 over the past year. Five-year average earnings growth is -237.67%. The latest quarter delivered EPS of $0.07. The next quarter is forecast at -$0.10. Next year's EPS is expected at $54.26. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.50 to $3.00. The high target offers 23.32% upside. The low target suggests -32.74% downside. The mean target is $4.01. This offers -10.09% upside. Clover Health Investments, Corp. earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by 81.16%. The prior quarter beat by -28.57%. Over the last six quarters, Apple has recorded several small beats. These include -171.43% in May 06, 2025.

Clover Health Investments, Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.23. This means the shares are trading below this model’s fair value.

Clover Health Investments, Corp. (NASDAQ:CLOV) closed at $4.46 USD, losing -$0.08 (-1.76%) from the previous close of $4.54. The stock is currently mid-range between its 52-week high and low $1.58 and $5.59. With a market capitalization of about $2.31 billion, Clover Health Investments, Corp. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.48). Key stats such as the average daily volume over the past year has been around 5.00 million shares, in line with its 52-week average. Headquartered in Wilmington, DE, Clover Health Investments, Corp. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Andrew Toy, the company employs approximately 724 people and listed since June 12, 2020. Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance.

Clover Health Investments, Corp. trades at a P/E ratio of -110.49, slightly below the S&P 500 average, with a price-to-sales ratio of 0.94 and a price-to-book ratio of 6.23 trading at moderately above to book value. The P/FCF stands at 31.25, also above market averages.

Our AI price prediction model suggests that Clover Health Investments, Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.19%, with price expected at $4.87 by October 02, 2026, within a range of $4.66 to $5.10 3-Month Outlook: Projected rise of 28.92%, reaching $5.75 by December 17, 2026, with a range of $5.42 to $6.11. 1-Year Outlook: Projected gain of 650.0%, with price at $33.45 by September 17, 2027, within a range of $36.42 to $41.06.

Clover Health Investments, Corp. (NASDAQ:CLOV) shares are up 10.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Clover Health Investments, Corp. trading at a premium to the broader market with a P/E of -110.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.74, suggesting 28.7% upside. Our AI forecast model points to short-term strength (9.19% over two weeks), a medium-term rise (28.92% over three months), and a longer-term gain (650.0% over one year), with expected trading ranges indicating moderate volatility.